



# 2023 Open Hearing on Reports of the Policy Review Committee & House Rules Review Committee

Wednesday, January 11, 2023  
2:00pm – 3:00pm ET

*For Every Pharmacist. For All of Pharmacy.*

[pharmacist.com](https://www.pharmacist.com)

# Objectives

1. Review the 2022-2023 House Rules Review Committee Report
2. Review the 2022-2023 Policy Review Committee Report
3. Briefly discuss next steps in the process

Webinar scheduled for 60 minutes:

10 mins for intro/overview

15 mins House Rules Review Committee

15 mins Policy Review Committee

20 mins for final comments/questions and next steps

# Webinar Process

To request to speak during the webinar, click on the **raise hand** button. You will be placed in the queue and recognized by the moderator.

Provide written questions/comments through the **question panel** or send an email to **HOD@aphanet.org**. Written comments may be limited due to time but will be made available to the Policy Committee.

The moderator, chairs, and APhA Staff will clarify issues but will not engage in debate. Be courteous to your colleagues in your communications.

We want your perspective to ensure other delegates are better informed on policies and proposals up for review and debate during the March 2023 House session.

# APhA Antitrust Statement

The American Pharmacists Association complies with all Federal and State Antitrust laws, rules and regulations. Therefore:

- 1) Meetings will follow a formal, pre-approved agenda which will be provided to each attendee. Participants at meetings should adhere strictly to the agenda. Subjects not included on the agenda should generally not be considered at the meeting.
- 2) The agenda will be specific and will prohibit discussions or recommendations regarding topics that may cause antitrust problems, such as prices or price levels. In addition, no discussion is permitted of any elements of a company's operations which might influence price such as:
  - 1) Cost of operations, supplies, labor or services;
  - 2) Allowance for discounts;
  - 3) Terms of sale including credit arrangements; and,
  - 4) Profit margins and mark ups, provided this limitation shall not extend to discussions of methods of operation, maintenance, and similar matters in which cost, or efficiency is merely incidental.
- 3) It is a violation of Antitrust laws to agree not to compete, therefore, discussions of division of territories or customers or limitations on the nature of business carried on or products sold are not permitted.
- 4) Boycotts in any form are unlawful. Discussion relating to boycotts is prohibited, including discussions about blacklisting or unfavorable reports about particular companies including their financial situation.
- 5) Whenever discussion borders on an area of antitrust sensitivity, the Association's representative should request that the discussion be stopped and ask that the request be made a part of the minutes of the meeting being attended. If others continue such discussion, the webinar will be terminated.



# House Activities Since March 2022

- House Rules Review Committee
- Policy Review Committee

# HOD Activity Since March 2022

- House Rules Review Committee
  - In depth review of House operations
  - Recommendation to the Board of Trustees not to hold a Fall Virtual House in November 2022
- Policy Review Committee
  - Retain – 59
  - Archive – 5
  - Amend – 1
  - Rescind – 0



# 2022-2023 House Rules Review Committee Recommendations

Report for March 2023 House Session at APhA2023 in Phoenix, AZ

# House Rules Review Committee Report

## 2022-2023 House Rules Review Committee Members

- Lucinda Maine, Chair
- Adriane Irwin
- Nimit Jindal
- Cathy Kuhn
- Terri Moore
- Kevin Musto
- Brent Reed



# House Rules Review Committee Report

## Proposed Guidance

- Guidance for a Fall 2022 Virtual House of Delegates Session
- Unfilled Delegate Seats
- Motion to Refer
- State Caucus Support / Expansion Efforts
- Consent Agenda Process
- Policy Review Committee
- Urgent New Business Item Process

## Recommended Rule Change

- Rule 13 – New Business

# House Rules Review Committee Report

## Guidance for a Virtual Fall 2022 House of Delegates Session

- Recommendation not to hold a Fall Virtual House of Delegates session

## Unfilled Delegate Seats

- Existing inactivated delegate seats prior to March 2020 will remain in effect and delegation coordinators are able to follow the existing processes to reactivate those seats upon request.
- No updates are needed to the process for requesting reactivation of an inactivated delegate seat.

## Motion to Refer

- The Committee recommends the Speaker of the House have the ability to facilitate further discussion on an item based on the flow of the House session.

# House Rules Review Committee Report

## State Caucus Support / Expansion Efforts

- The committee recommends development of additional opportunities for delegations to caucus and network, during the annual meeting and virtual house sessions, and beyond.

## Consent Agenda Process

- The committee recommends continuation of existing guidance to conduct an electronic poll in advance of an in-person March House session to encompass policy recommendations from committees.

## Policy Review Committee

- The committee recommends two methods for the committee to review existing policies by topic, with a purpose of ensuring uniformity across related statements or amending to contemporary language.

# House Rules Review Committee Report

## Urgent New Business Item Process

- Access to language and background information of urgent new business items was an issue observed in the March 2022 House sessions.
- When two house sessions are scheduled to handle regular business of the House, then no action should be taken on urgent new business items during the first session of the House.
- Existing House Rule 13 already outlines how urgent new business items are to be handled when a new business open hearing is scheduled to take place.
  - *“Approved urgent items shall be considered with other New Business Items and discussed during the New Business Open Hearing, if one is scheduled to take place. Appropriate action will be recommended by the New Business Review Committee in the same manner as other New Business Items.”*

# House Rules Review Committee Report

## Urgent New Business Item Process (cont)

- Existing House Rule 13 does not address what should occur when a new business open hearing is not scheduled nor when only a single session of the House is scheduled.
- The Committee recommends that any urgent new business item have adequate time for review by delegates of background material prior to debate on any item.
- In addition to existing House Rule 6 where the Speaker develops the agenda for all House session in consultation with the Secretary, the Speaker of the House may integrate time for Delegate review for urgent new business items.
- The Committee recommends an addition to House Rule 13 to emphasize the need for adequate time for review of urgent new business items.

# House Rules Review Committee Report

## Rule 13 New Business – Proposed Modifications

An urgent item can be considered, without a suspension of the House rules, if presented to the Speaker, with necessary background information, at least 24 hours prior to the beginning of any House session. Urgent items are defined as matters that, due to the nature of their content, must be considered by the House outside of the normal policy processes. The House leadership (Speaker, Speaker-elect [when present], and Secretary) will evaluate submitted urgent items based on the timely and impactful nature of the presented item and determine if the urgent item is to be approved as New Business. The House shall then be informed of any approved urgent items to be considered by the House as soon as is possible by the Speaker. Approved urgent items shall be considered with other New Business Items and discussed during the New Business Open Hearing, if one is scheduled to take place. No immediate action shall be taken on urgent new business items without prior review of proposed statements and background information by all delegates. Appropriate action will be recommended by the New Business Review Committee in the same manner as other New Business Items. Urgent items denied consideration by House Officers may still be addressed by the House, with a suspension of House rules at the House session where New Business will be acted upon.

# House Rules Review Committee Report

## Rule 13 New Business – Proposed Modifications

The New Business Review Committee's recommendations will be addressed by the House of Delegates in the following order:

1. New Items submitted by the Policy Review Committee
2. General New Business Items
3. Urgent New Business Items

If the New Business Review Committee recommends no action on a New Business Item, the Speaker of the House shall place the New Business Item before the House of Delegates for consideration and action. Each whole-numbered statement within the New Business Item should ~~shall~~ be considered separately. A consent agenda process may be used to consider multiple recommendations within a single New Business Item, in accordance with Robert's Rules of Order. Consideration of the New Business Item in its entirety requires suspension of House rules.



# Opportunity for Discussion

- **House Rules Review Committee Report**



# House Rules Review Committee Report

## Proposed Guidance

- Guidance for a Fall 2022 Virtual House of Delegates Session
- Unfilled Delegate Seats
- Motion to Refer
- State Caucus Support / Expansion Efforts
- Consent Agenda Process
- Policy Review Committee
- Urgent New Business Item Process

## Proposed Rule Changes

- **Rule 13** – New Business

***Time for Discussion***



# 2022-2023 Policy Review Committee Recommendations

Report for March 2023 House Session at APhA2023 in Phoenix, AZ

# Policy Review Committee Report

## 2022-2023 Policy Review Committee Members

- Christopher Harlow, Chair
- Grace Baek
- Kelly Fine
- Jessica Hinson
- Cory Holland
- Mary Klein
- Adrienne Simmons
- Scott Tomerlin
- Taylor Williams

# Policy Review Committee Report

## Charges

1. Policy that has not been reviewed or revised in the past 10 years;
2. Policy related to statements adopted in the most recent House session (from March 2022)
3. Contemporary issues, if applicable, as identified by the Speaker.
  - Based on feedback from Delegates, the Speaker of the House charged the Committee to review all APhA policies for potential statements that may impact the scope of practice of non-pharmacist health care professionals.

<b>Charge 1</b>	0 Recommendations
<b>Charge 2</b>	38 Recommendations
<b>Charge 3</b>	27 Recommendations

# Policy Review Committee Report

## Potential Recommendations

- Retain
- Amend
- Archive
- Rescind

## Policy Review Committee Report

### 65 Total Recommendations for Action by the House

Upon reviewing all currently adopted APhA policies, the committee provided 65 recommendations related to newly adopted policy from the March 2022 House of Delegates.

- Recommend to Retain – **59**
- Recommend to Amend – **1**
- Recommend to Archive – **5**
- Recommend to Rescind – **0**

## Policy Review Committee - Archive

### Recommend to Archive – Item #60

#### **2013, 1978 Pharmacists Providing Health Care Services**

1. APhA supports the study and development of new methods and procedures whereby pharmacists can increase their ability and expand their opportunities to provide health care services to patients

(Am Pharm. NS18(8):47; July 1978) (Reviewed 2007) (Reviewed 2008) (JAPhA. 53(4):366; July/August 2013) (Reviewed 2016).

**Comments:** The Policy Review Committee recommends ARCHIVING the above policy statement as more contemporary policy exists and this statement is duplicative to statement 1 in 2004, *1978 Roles in Health Care for Pharmacists*.

## Policy Review Committee - Archive

### Recommend to Archive – Item #61

#### 2013, 1980 Medication Selection by Pharmacists

1. APhA supports the concept of a team approach to health care in which health care professionals perform those functions for which they are educated. APhA recognizes that the pharmacist is the expert on drugs and drug therapy on the health care team and supports a medication selection role for the pharmacist, based on the specific diagnosis of a qualified health care practitioner.

(Am Pharm. NS20(7):62; July 1980) (Reviewed 2003) (Reviewed 2007) (Reviewed 2008) (Reviewed 2009) (Reviewed 2011) (Reviewed 2012) (JAPhA. 53(4):366; July/August 2013) (Reviewed 2018)

**Comments:** The Policy Review Committee recommends ARCHIVING the above statement as there is more contemporary policy (2022 *Standard of Care Regulatory Model for State Pharmacy Practice Acts*, 2017; 2012 *Contemporary Pharmacy Practice*; 2022 *Pharmacists' Application of Professional Judgment*) that supports a more expansive role of pharmacists that is not limited to only medication selection.



## Policy Review Committee - Archive

### Recommend to Archive – Item #62

#### **2003, 1992 The Pharmacist's Role in Therapeutic Outcomes**

1. APhA affirms that achieving optimal therapeutic outcomes for each patient is a shared responsibility of the health care team.
2. APhA recognizes that a primary responsibility of the pharmacist in achieving optimal therapeutic outcomes is to take an active role in the development and implementation of a therapeutic plan and in the appropriate monitoring of each patient.

(Am Pharm. NS32(6):515; June 1992) (JAPhA. NS43(5)(suppl 1):S57; September/October 2003) (Reviewed 2007) (Reviewed 2009) (Reviewed 2010) (Reviewed 2011) (Reviewed 2016) (Reviewed 2016)

**Comments:** The Policy Review Committee recommends ARCHIVING the above policy statements as there is more contemporary policy (2020 Community-Based Pharmacists as Providers of Care; 2017 Patient Access to Pharmacist-Prescribed Medications; 2019 Referral System for the Pharmacy Profession; 2020 Accountability of Pharmacists) that covers the intent of the existing policy.

## Policy Review Committee - Archive

### Recommend to Archive – Item #63

#### **2004, 1977 Pharmacy Practice Professional Judgement**

1. APhA supports a pharmacist's right, regardless of place or style of practice, to exercise individual professional judgment and complete authority for those individual professional responsibilities assumed.
2. APhA supports decision-making processes that ensure the opportunity for input by all pharmacists affected by the decisions.

(JAPhA. NS17:463; July 1977) (JAPhA NS44(5):551; September/October 2004) (Reviewed 2007) (Reviewed 2012) (Reviewed 2017) (Reviewed 2020)

**Comments:** The Policy Review Committee recommends ARCHIVING the above policy statements as the new *2022 Pharmacists' Application of Professional Judgment* policy is more contemporary and captures the intent of these older policy statements.

## Policy Review Committee - Archive

### Recommend to Archive – Item #64

#### **1999 Sale of Sterile Syringes**

1. APhA encourages state legislatures and boards of pharmacy to revise laws and regulations to permit the unrestricted sale or distribution of sterile syringes and needles by or with the knowledge of a pharmacist in an effort to decrease the transmission of blood-borne diseases.

(JAPhA. 39(4):447; July/August 1999) (Reviewed 2003) (Reviewed 2006) (Reviewed 2008) (Reviewed 2009) (Reviewed 2014) (Reviewed 2019) (Reviewed 2020)

**Comments:** The Policy Review Committee recommends ARCHIVING the above policy statements as there is more contemporary policy outlined in statements four and five of the 2019 Patient-Centered Care of people Who Inject Nonmedically Sanctioned Psychotropic or Psychotropic Substances policy, that covers the intent of this older policy.

## Policy Review Committee - Amend

### Recommend to Amend – Item #65

#### **2016 Medications for Substance Use Disorders Medication-Assisted Treatment**

1. APhA supports expanding access to medications indicated for opioid use disorders (MOUDs) and other substance use disorders, ~~-assisted Treatment (MAT)~~ including but not limited to pharmacist-administered injection services for treatment and maintenance of substance use disorders that are based on a valid prescription.

(JAPhA. 56(4):370; July/August 2016) (Reviewed 2021)

**Comments:** The Policy Review Committee recommends AMENDING the above policy statement to use more contemporary language to describe this class of medications and align with related policy on this topic.



# Opportunity for Discussion



# Housekeeping Items & Next Steps

# How will these reports be handled in the APhA2023 House of Delegates?


## Use of an Electronic Poll

- Consent Agenda Process
  - Delegates submit responses on individual motions through an electronic poll
  - Motions that receive **at least 75%** approval are added into a consent agenda
    - Consent agenda is handled with a singular motion
    - Delegates can pull any item from the consent agenda for separate debate and voting without debate
  - Motions that receive **less than 75%** approval are added into the regular House agenda for individual action



# Use of an Electronic Poll

## Process to handle Policy Review Committee Report



# Housekeeping & Next Steps

**Reminder:** Sign-up as a delegate if you have not already done so!

Contact your state pharmacy association, APhA Academy, or affiliated organization.

**Reminder:** Register for our next House of Delegates webinars

## Open Hearing on New Business Items

- Wed, Feb 1, 2023 – 3:00 PM - 4:30 PM (ET)
- Wed, Feb 8, 2023 – 6:00 PM - 7:30 PM (ET)

## Open Hearing on House 2023 Session Materials

- Wed, Feb 15, 2023 – 2:00 PM - 3:00 PM (ET)
- Wed, Feb 22, 2023 – 6:00 PM – 7:00 PM (ET)

# REGISTRATION

**REGISTER NOW >**

**SCAN ME**



**First Session of the House of Delegates in Phoenix, AZ**


**March 24 from 2:45pm – 5:15pm**

**Second Session of the House of Delegates in Phoenix, AZ**

**March 27 from 1:30pm – 4:30pm**

# Upcoming Caucus Opportunities

- Check the APhA2023 Schedule of Events for updates on State and Local Caucuses
- Expansion of Delegate Caucus Opportunities & Networks



# Continue the Conversation

APhA Engage makes joining the conversation easy!

1. Visit [engage.pharmacist.com](https://engage.pharmacist.com)
2. Login using your APhA username and password
3. Click “Participate” then “Join a Community”
4. Find one of the three the “HOD Issue” communities
5. Click “Join” and follow the prompts on your screen





# Thank you!

Contact HOD Staff or submit additional questions or comments at [hod@aphanet.org](mailto:hod@aphanet.org)

*For Every Pharmacist. For All of Pharmacy.*

[pharmacist.com](http://pharmacist.com)